



PRESS RELEASE

For immediate release

PERCEPTRONIX LAUNCHES LUNGSIGN.COM: PROVIDING EXCITING INFORMATION ON INNOVATIVE TECHNOLOGY THAT BRINGS NEW HOPE TO THOSE AT RISK FOR LUNG CANCER

VANCOUVER, CANADA (June 6, 2007) - Perceptronix Medical Inc. ("Perceptronix"), a private biotechnology company focused on detecting cancer at early stages, is pleased to announce the launch of its new website, www.lungsign.com. LungSign.com is designed to be a primary resource for patients and healthcare providers interested in the early detection of lung cancer.

The prognosis for lung cancer has not improved over the past 10 years: the 5-year relative survival rate for all stages of lung cancer combined is only 15%. When it comes to any cancer, research shows that early detection is key to extending lives and improving the quality of life for those who are ill. When lung cancer is found early and treated before it has spread to lymph nodes or other organs, the average 5-year relative survival rate increases to 49%.

LungSign.com provides information on Perceptronix' innovative LungSign™ technology that will revolutionize the process of detecting cancer at its earliest stages. LungSign™ is a safe, simple and non-invasive test used to assess a patient's risk of lung cancer.

"We are very excited about launching this new website", commented Rohini Hira, Vice President Sales & Marketing for Perceptronix. "Patients are in a constant search for information about their health and healthcare providers are always assessing new and improved ways to evaluate their patients' conditions. The new website, LungSign.com is our way of providing a comprehensive education and information resource for those interested in the early detection of lung cancer."

LungSign™ is the first test to market that provides both an independent result to help with the early detection of lung cancer and a useful complement to current radiological diagnostic methods. LungSign™ is based on an innovative marker in sputum, called malignancy associate changes (MAC), that is highly correlated with the presence of lung malignancy — even in early-stage disease. By analyzing the lung cells commonly found in sputum, LungSign™ can detect cancer before it spreads, increasing the likelihood of successful treatment.

Dr. Roger Kemp, a key scientist involved in the development of LungSign™ further explained, "Laboratories will benefit from using LungSign™ as it is a significant improvement over conventional cytology or marker-based tests, which rely on the presence of abnormal cells to detect lung cancer. We expect the use of LungSign™ to enable cancer detection at the earliest stage which is key to improving patient outcomes."

About LungSign™

LungSign™ is based on the ClearSign technology platform developed by Perceptronix. LungSign™ is a safe, simple, non-invasive test used to assess a patient's risk of developing



lung cancer. By analyzing the lung cells commonly found in sputum, LungSign™ can detect cancer before it spreads, increasing the likelihood of successful treatment.

It has been designed to test for early-stage, pre-symptomatic lung cancer in high-risk individuals — men and women over 50 years old, with a history of cigarette smoking, exposure to second-hand smoke, or significant exposure to carcinogens such as radon and asbestos. In addition, for patients who have had CT scans that found small, possibly cancerous nodules, LungSign™ results may help shorten the diagnostic process.

About Perceptronix Medical Inc. (www.perceptronix.com)

Perceptronix Medical Inc. (founded in 1999) is a private cancer diagnostics company based in Vancouver, Canada. Perceptronix commercializes early cancer detection technologies developed in partnership with the BC Cancer Agency, a world-leader in cancer care and research, with a particularly notable track record in pioneering early cancer detection programs. Perceptronix is focused on offering quantitative image cell analysis services for early cancer detection. Perceptronix' products and services offer an improvement over existing detection and localization technologies and provide physicians with increased options for prolonging and improving the quality of patients' lives.

This news release is not, and under no circumstances, to be construed as, an advertisement, solicitation or offering of securities of Perceptronix Medical Inc. The statements made in this news release may contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the Company's expectations.

Media Contact:

Amanda Smith, BSc

Smith Biotech

Phone: (778) 846-4116

amanda@smithbiotech.com